spacer
spacer

Jump to: InterProScan Databases Documentation FTP site Help Advanced search

InterPro: IPR002477 Peptidoglycan binding-like

Protein matchesHelp
UniProtKB
Matches:
4056 proteins
AccessionHelp IPR002477 Peptidoglycan-bd-like
SecondaryHelp IPR009070
TypeHelp Domain
SignaturesHelp
InterPro RelationshipsHelp
Found in IPR004555 OpcA
IPR014224 Spore cortex-lytic enzyme SleB
IPR016293 Peptidase M10A, matrix metallopeotidase
GO Term annotationHelp
Process GO:0008152 metabolic process
InterPro annotation
BioMart Logo Entry Details in BioMart
AbstractHelp

This entry represents peptidoglycan binding domain (PGBD), as well as related domains that share the same structure. PGBD may have a general peptidoglycan binding function, has a core structure consisting of a closed, three-helical bundle with a left-handed twist. It is found at the N or C terminus of a variety of enzymes involved in bacterial cell wall degradation [1, 2, 3]. Examples are:

  • Muramoyl-pentapeptide carboxypeptidase (EC:3.4.17.8)
  • N-acetylmuramoyl-L-alanine amidase cwlA precursor (cell wall hydrolase, autolysin, EC:3.5.1.28)
  • Autolytic lysozyme (1,4-beta-N-acetylmuramidase, autolysin, EC:3.2.1.17)
  • Membrane-bound lytic murein transglycosylase B
  • Zinc-containing D-alanyl-D-alanine-cleaving carboxypeptidase, VanX [4].

Many of the proteins having this domain are as yet uncharacterised. However, some are known to belong to MEROPS peptidase family M15 (clan MD), subfamily M15A metallopeptidases. A number of the proteins belonging to subfamily M15A are non-peptidase homologues as they either have been found experimentally to be without peptidase activity, or lack amino acid residues that are believed to be essential for the catalytic activity.

Eukaryotic enzymes can contain structurally similar PGBD-like domains. Matrix metalloproteinases (MMP), which catalyse extracellular matrix degradation, have N-terminal domains that resemble PGBD. Examples are gelatinase A (MMP-2), which degrades type IV collagen [5], stromelysin-1 (MMP-3), which plays a role in arthritis and tumour invasion [6, 7], and gelatinase B (MMP-9) secreted by neutrophils as part of the innate immune defence mechanism [8]. Several MMPs are implicated in cancer progression, since degradation of the extracellular matrix is an essential step in the cascade of metastasis [9].

Structural linksHelp
PDB - click here
SCOP: a.20.1.1 , a.20.1.2
Database linksHelp
Enzyme: EC:3
PANDIT: PF01471
Blocks: IPB002477
MEROPS: M15
Pfam Clan: CL0244.5

Taxonomic coverageHelp

Overlapping InterPro entriesHelp
IPR002477 Numbers of overlapping proteins Average numbers of overlapping amino acids

Example proteinsHelp
O55760 Uncharacterized protein 162R

O60882 Matrix metalloproteinase-20

P00733 Zinc D-Ala-D-Ala carboxypeptidase

P33435 Collagenase 3

P73720 Putative OxPP cycle protein opcA

More proteins


Example Proteins Key


InterPro entry accession number/name and structure databases Colour code
IPR013230 Peptidase M15A, C-terminal
IPR001818 Peptidase M10A/M12B, matrixin/adamalysin
IPR006026 Peptidase, metallopeptidases
IPR000585 Hemopexin/matrixin
IPR016293 Peptidase M10A, matrix metallopeotidase
IPR019297 Glucose-6-phosphate dehydrogenase subunit
IPR002477 Peptidoglycan binding-like
IPR004555 OpcA
IPR018487 Hemopexin/matrixin, repeat
IPR018486 Hemopexin/matrixin, conserved site
IPR009045 Hedgehog/DD-peptidase, zinc-binding motif
PDB Chain
ModBase
CATH Domain
SWISS-MODEL
SCOP Domain

PublicationsHelp
1. Krogh S, Jorgensen ST, Devine KM.
Lysis genes of the Bacillus subtilis defective prophage PBSX.
J. Bacteriol. 180 2110-7 1998 [PubMed: 9555893]
http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=9555893&action=stream&blobtype=pdf
2. Dideberg O, Charlier P, Dive G, Joris B, Frere JM, Ghuysen JM.
Structure of a Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase at 2.5 A resolution.
Nature 299 469-70 1982 [PubMed: 7121588]
http://dx.doi.org/10.1038/299469a0
3. Foster SJ.
Cloning, expression, sequence analysis and biochemical characterization of an autolytic amidase of Bacillus subtilis 168 trpC2.
J. Gen. Microbiol. 137 1987-98 1991 [PubMed: 1683402]
4. Charlier P, Dideberg O, Jamoulle JC, Frere JM, Ghuysen JM, Dive G, Lamotte-Brasseur J.
Active-site-directed inactivators of the Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase of Streptomyces albus G.
Biochem. J. 219 763-72 1984 [PubMed: 6743245]
http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=6743245
5. Seiki M.
Membrane-type matrix metalloproteinases.
APMIS 107 137-43 1999 [PubMed: 10190290]
6. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP.
Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
Ann. Rheum. Dis. 62 635-8 2003 [PubMed: 12810425]
http://dx.doi.org/10.1136/ard.62.7.635
7. Hornebeck W, Maquart FX.
Proteolyzed matrix as a template for the regulation of tumor progression.
Biomed. Pharmacother. 57 223-30 2003 [PubMed: 12888258]
http://dx.doi.org/10.1016/S0753-3322(03)00049-0
8. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G.
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities.
Eur. J. Biochem. 270 3739-49 2003 [PubMed: 12950257]
http://dx.doi.org/10.1046/j.1432-1033.2003.03760.x
9. Yoshizaki T, Sato H, Furukawa M.
Recent advances in the regulation of matrix metalloproteinase 2 activation: from basic research to clinical implication (Review).
Oncol. Rep. 9 607-11 2002 [PubMed: 11956636]

Additional ReadingHelp
Alcaraz LA, Banci L, Bertini I, Cantini F, Donaire A, Gonnelli L.
Matrix metalloproteinase-inhibitor interaction: the solution structure of the catalytic domain of human matrix metalloproteinase-3 with different inhibitors.
J. Biol. Inorg. Chem. 12 2007 1197-206 [PubMed: 17710450]
http://dx.doi.org/10.1007/s00775-007-0288-9
Kohno T, Hochigai H, Yamashita E, Tsukihara T, Kanaoka M.
Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.
Biochem. Biophys. Res. Commun. 344 2006 315-22 [PubMed: 16603129]
http://dx.doi.org/10.1016/j.bbrc.2006.03.098
Iyer S, Visse R, Nagase H, Acharya KR.
Crystal structure of an active form of human MMP-1.
J. Mol. Biol. 362 2006 78-88 [PubMed: 16890240]
http://dx.doi.org/10.1016/j.jmb.2006.06.079
Tochowicz A, Maskos K, Huber R, Oltenfreiter R, Dive V, Yiotakis A, Zanda M, Pourmotabbed T, Bode W, Goettig P.
Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity.
J. Mol. Biol. 371 2007 989-1006 [PubMed: 17599356]
http://dx.doi.org/10.1016/j.jmb.2007.05.068
Iyer S, Wei S, Brew K, Acharya KR.
Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1.
J. Biol. Chem. 282 2007 364-71 [PubMed: 17050530]
http://dx.doi.org/10.1074/jbc.M607625200
Gooley PR, O'Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL, Hermes JD, Esser CK, Hagmann WK, Springer JP.
The NMR structure of the inhibited catalytic domain of human stromelysin-1.
Nat. Struct. Biol. 1 1994 111-8 [PubMed: 7656014]
http://dx.doi.org/10.1038/nsb0294-111
spacer
spacer
InterPro 23.1